Fundraising

Vir Biotechnology

Vir Biotechnology Raises $250M in Series E

2016
Founded
500+
Employees
499 Illinois Street, San Francisco, CA 94158
2 min read

Quick Facts

Vir Biotechnology Raises $250M in Series E


Vir Biotechnology has successfully raised $250M in a Series E at a $3.3B valuation led by SoftBank Vision Fund, Arch Venture Partners, ARCH Venture Partners, Intermediate Capital Group.


Company Overview


Vir Biotechnology is a Biotech company headquartered in 499 Illinois Street, San Francisco, CA 94158, founded in 2016 with 500+ employees.


Infectious disease treatment development


Fundraising Details


  • Amount Raised: $250M
  • Round Type: Series E
  • Valuation: $3.3B
  • Date: 2024-01-29
  • Investors: SoftBank Vision Fund, Arch Venture Partners, ARCH Venture Partners, Intermediate Capital Group

About Vir Biotechnology


Infectious disease treatment development The company is positioned in the Biotech sector, serving a growing market with innovative solutions.


Key Information


  • Headquarters: 499 Illinois Street, San Francisco, CA 94158
  • Founded: 2016
  • Team Size: 500+
  • Industry: Biotech

What This Means


This funding round demonstrates strong investor confidence in Vir Biotechnology's vision and execution. The capital will likely be used to:


  • Scale Operations: Expand the team and operational capacity
  • Product Development: Enhance existing products and develop new features
  • Market Expansion: Enter new markets and strengthen presence in existing ones
  • Technology Investment: Invest in infrastructure and technology capabilities

Industry Context


The Biotech sector continues to attract significant investment as companies innovate to meet evolving market demands. Vir Biotechnology's successful fundraising reflects the strong fundamentals and growth potential in this space.


Valuation Milestone


Reaching a $3.3B valuation marks an important milestone for Vir Biotechnology, positioning the company among notable players in the Biotech industry.


Looking Ahead


With this new capital, Vir Biotechnology is well-positioned to execute on its growth strategy and continue building innovative solutions in the Biotech space. The company's trajectory will be one to watch as it deploys this funding to achieve its next phase of growth.


This fundraising news was reported on 2024-01-29. For more information about Vir Biotechnology, visit their headquarters at 499 Illinois Street, San Francisco, CA 94158.

About the Author

Fundraising News Team
Fundraising News Team
Tracking the latest funding rounds and investment news